Published within
|«
«
|
1
|
2
|
3
|
4
|
5
|
6
|
7
|
8
|
9
|
...
|
»
»|
| Type |
Product title / description
|
Pub
|
Price |
CommentWire
|
With Abbott's Humira (adalimumab) being reimbursed by 95% of managed care organizations three months after its US launch, the company has re-forecast the product's 2003 results. Abbott is under pressure to build US share rapidly, before the expected 2005 launch of Celltech/Pharmacia/Pfizer's rival rheumatoid arthritis drug CD870.
Published By Datamonitor
|
16 Apr 2003 |
|
CommentWire
|
A new article in the Journal of the American Medical Association reveals that interleukin-12/23 inhibitors such as Abbott's Ozespa do not raise cardiovascular risks in psoriasis patients compared to placebo or TNF inhibitors. Abbott will welcome the news, but Datamonitor believes that while Ozespa is a key contender if resubmitted for approval, hurdles remain as more extensive data are needed.
Published By Datamonitor
|
24 Aug 2011 |
|
CommentWire
|
Following a regulatory recommendation, Abbott Laboratories has suspended sales of its controversial obesity drug Reductil in Europe (branded elsewhere as Meridia and Sibutrex). Meanwhile, the FDA has called for new contraindications to be added to the drug's label following data from the SCOUT trial. These issues highlight the commercial risks inherent in targeting the burgeoning obesity market.
Published By Datamonitor
|
22 Jan 2010 |
|
CommentWire
|
Global healthcare firm Abbott has boosted its gonadotropin releasing hormones pipeline through a deal with Neurocrine for the continued development of new promising candidate elagolix. The partnership is favorable for both parties, with Abbott seeking to maintain its endometriosis market leadership after Lupron's patent expiry in 2014.
Published By Datamonitor
|
17 Jun 2010 |
|
CommentWire
|
Abgenix and Amgen plan to submit an application to market colon cancer drug panitumumab by the end of 2005 after US regulators awarded the drug fast track status. With this indication already dominated by Genentech's Avastin and ImClone's Erbitux, panitumumab will need to demonstrate a survival advantage in phase III testing in order to establish itself in the colon cancer drug market.
Published By Datamonitor
|
03 Aug 2005 |
|
CommentWire
|
Results from a recent clinical trial have demonstrated that Acadia's ACP-103 improves quality of sleep by increasing slow wave sleep. This suggests that ACP-103 has potential as a novel treatment for sleep maintenance insomnia. However, more trials with larger patient samples are needed and the drug candidate has many hurdles to overcome before it can claim a place in the crowded insomnia market.
Published By Datamonitor
|
21 Apr 2006 |
|
CommentWire
|
The FDA has approved Acorda's Ampyra for the symptomatic treatment of multiple sclerosis, making it the first therapeutic option approved to address walking impairments experienced by patients with the disease. However, despite favorable efficacy data, prescriptions are likely to be limited by price concerns and the risk of seizures.
Published By Datamonitor
|
27 Jan 2010 |
|
Expert View
|
Datamonitor recently attended this year's American College of Rheumatology Annual Conference in Philadelphia. No ground-breaking data for rheumatoid arthritis therapies were presented; instead, systemic lupus erythematosus stole the limelight. Human Genome Sciences' Benlysta in particular generated a stir, being the first drug in this indication to generate positive data at Phase III.
Published By Datamonitor
|
23 Oct 2009 |
|
CommentWire
|
Actelion and GlaxoSmithKline have discontinued development of their Phase III insomnia candidate, almorexant, following a review of clinical data. The drug, an orexin receptor antagonist, had been widely regarded by leading sleep disorder specialists as an innovative and promising insomnia treatment. Termination of the drug's development casts doubt over the future of the drug class.
Published By Datamonitor
|
28 Jan 2011 |
|
Expert View
|
Results from the GRAVITAS trial suggest that there is no benefit in treating low-risk post-percutaneous coronary intervention patients with high residual platelet activity with a double dose of clopidogrel. The results are not definitive, however: it was a relatively small trial performed in relatively low-risk patients, and may have been insufficiently powered.
Published By Datamonitor
|
29 Nov 2010 |
|
|«
«
|
1
|
2
|
3
|
4
|
5
|
6
|
7
|
8
|
9
|
...
|
»
»|
No help is available.
Reports and briefs contain analyst driven analysis and opinion covering a specific market or issue.
Business Insight reports are an objective source of data, analysis and market insight
Insight for technology vendors into customer trends and pain points from key business decision makers.
Butler Group's thought leadership, opinion, with end user case studies and product profiles for key vendors.
Butler Group's vendor ranking and assessment model groups vendors into Outperform, Perform, and Under-perform categories.
Butler Group's thought leadership, opinion, and best practice with technology audits, product comparisons and rankings.
Opinion and market commentary from Datamonitor's industry experts.
Company profiles deliver detailed insight into how companies are organized and function with SWOT analysis.
Company reports provide detailed company evaluations.
Opinion and market commentary from Datamonitor's industry experts.
Company reports provide detailed company evaluations.
Opinion and market commentary from Datamonitor's industry experts.
Opinion and market commentary from Datamonitor's industry experts.
Track industry events, markets, products, customers, prospects, competitors and partners
Country profiles presenting easy-to-digest summaries and standardized data.
Databooks use charts and tables to provide a data-centric view of a particular market or category
Opinion and market commentary from Datamonitor's industry experts.
Comprehensive category data, including market value, volume, segmentation and share, with analysis.
Industry profiles provide standardized market data (including size & segmentation) and competitive analysis.
Market sizing and forecast data for a market or sector delivered in spreadsheet format.
Track industry events, markets, products, customers, prospects, competitors and partners
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Reports and briefs contain analyst driven analysis and opinion covering a specific market or issue.
Opinion and market commentary from Datamonitor's industry experts.
Insight for technology vendors into customer trends and pain points from key business decision makers.
Business information covering a specific market or issue.